GBG Forschungs GmbH

Noch auf der Suche nach einem tollen Weihnachtsgeschenk? 🎁 Dann melde dich für das 22. Annual Scientific Meeting 2025 an!   Wir freuen uns Sie auch #2025 wieder zu unserem 2- tägigen, international besetzten 22. Annual Scientific Meeting einladen zu dürfen. Zusätzlich nehmen wir eine bisherige Tradition wieder auf und bieten unsere 3. Study Coordinating Conference am Vortag an. 📌 Veranstaltungsdetails Ort:        Hilton Frankfurt Airport, The Squaire  Datum:    ➡ 3. Study Coordinating Conference: Mittwoch, 05. März 2025            ➡ 22. Annual Scientific Meeting: Donnerstag, 06. März - Freitag, 07. März 2025  Format:     Hybride Veranstaltung mit Fokus auf Präsenz ✔️ Zu unseren wissenschaftlichen Veranstaltungen rund um das Thema Mammakarzinom informieren unsere #KOL über die aktuelle nationale und internationale Studienlage der German Breast Group und die allgemeinen wissenschaftlichen Trends. ✔️ In spezifischen #Workshops kann das Wissen vertieft und in Fachgesprächen vor Ort das eigene Netzwerk gepflegt werden. ✔️Als herausragende #Keynote Speaker unseres vielfältigen wissenschaftlichen Programms dürfen wir Herr Prof. Dr. Andrew Tutt sowie Prof. Dr. Jakob Kather ankündigen. Im Anschluss an unsere Veranstaltungen folgt am Samstag, den 08. März 2025, die "State of the Art“ Tagung der #AGO Mamma. Wie auch die Jahre zuvor, wird unsere Weiterbildungsveranstaltung von der Landesärztekammer Hessen mit Fortbildungspunkten zertifiziert. 👉 Melde dich heute noch an: https://extern.gbg.events/ GBG Forschungs GmbH #GBG #ASM22 #StudyCC #SpecialEvent #StudyCoordintor #AnnualMeeting

In this secondary analysis of the phase 3 PANTHER trial on adjuvant chemotherapy for high risk breast cancer, we attempt to identify subgroups that do not benefit from dose dense treatment. Subgroup analyses according to prognostic factors, subtypes and menopausal status, subpopulation treatment effect pattern plot analysis and the use of PREDICT could not identify any such patient group. Take home message: strongly consider dose dense chemotherapy for patients with high risk breast cancer and no medical contraindications. The study was published today in Lancet Regional Health Europe (IF 13.6) here: https://lnkd.in/dT7KN4X7 Thanks to all collaborators and participating patients. German Breast Group Austrian Breast & Colorectal Cancer Study Group (ABCSG) Karolinska Institutet Karolinska University Hospital #FoukakisGroup

🌟 Highlights from #SABCS24: #PADMA Trial Results in HR+/HER2- Metastatic Breast Cancer (mBC) 🌟 Excited to share the groundbreaking findings of the PADMA trial, presented at #SABCS24! This is the first prospective, randomized Phase IV trial comparing endocrine therapy (#ET) + CDK4/6 inhibitor with standard mono-#chemotherapy (± maintenance ET) as first-line #treatment for high-risk HR+/HER2- mBC. Key Outcomes 📈 Significant Improvement in Outcomes for ET + CDK4/6i Time-to-Treatment Failure (#TTF): Median: 17.2 months (ET + CDK4/6i) vs. 6.1 months (mono-chemotherapy) HR: 0.46, p<0.001 Progression-Free Survival (#PFS): Median: 18.7 months vs. 7.8 months HR: 0.45, p<0.001 📊 Trend for Overall Survival (#OS) Median OS: 46.1 months (ET + CDK4/6i) vs. 36.8 months (mono-chemotherapy) ✅ Safety: No new safety concerns observed. Implications These results support existing international guidelines advocating the use of ET + CDK4/6 inhibitors as the standard 1st-line therapy for HR+/HER2- mBC. The PADMA trial highlights a clear advantage in efficacy, supporting a shift away from chemotherapy-first approaches in eligible patients. A game-changer for optimizing patient outcomes! Full presentation is available on our website: https://lnkd.in/esBCW7eK #CancerResearch #BreastCancer #Oncology #GBG #ClinicalTrial

Scientific excellence at Goethe University: Six researchers are among the best in the world! 🌍 According to the current “Highly Cited Researchers” ranking by Clarivate, six researchers at our university are among the most cited researchers worldwide. This is an important indicator of the relevance and quality of their scientific work - and proof of the excellent research taking place at our university. The ranking includes around 6600 researchers from all over the world who are among the 1% most frequently cited in their respective subject area or interdisciplinary field. The high citation frequency shows that their publications are not only recognized internationally, but are also used and further developed by colleagues in the long term. → The evaluation is based on the “Web of Science” database and includes articles from the natural sciences, engineering, medicine, social sciences and economics that have been published in the last ten years. It only takes into account scientific journal articles - i.e. results that have been published accurately and peer-reviewed. The “Highly Cited Researchers” of our university at a glance: 🔬 Prof. Dr. Ivan Đikić - Institute of Biochemistry II (IBC2), expert in molecular cell biochemistry in the categories “Biology and Biochemistry” and “Molecular Biology and Genetics” ❤️ Prof. Dr. Stefanie Dimmeler - Institute for Cardiovascular Regeneration, Speaker of the Cluster of Excellence Cardio-Pulmonary Institute (CPI), awarded for her interdisciplinary research (“Cross Field”) 🧬 Prof. Dr. Florian Greten - tumor biologist and director of the Georg-Speyer-Haus, also listed in the “Cross Field” category 🧪 Prof. Dr. Gerhard Hummer - Institute of Biophysics, Director at the Max Planck Institute, “Cross Field” category apl. Prof. Dr. med. Sibylle Loibl - GBG Forschungs GmbH, outstanding in “Clinical Medicine” Prof. Dr. Stefan Offermanns - Center for Molecular Medicine, represented in the “Cross Field” category We are proud of this success and congratulate our “Highly Cited Researchers”! 🎉 🔗 Further information can be found here: https://lnkd.in/ezk9TyAK. #GoetheUni #Science #HighlyCitedResearchers #Research #Excellence #Researchers #Ranking #Clarivate #WebOfScience

A Personal Invitation from Our Conference Chair! Sibylle Loibl, Chair of #SGBCC2025, invites you to join us in Vienna this March! This year’s congress is set to be an incredible opportunity for sharing insights, exploring the latest advancements, and connecting with global leaders in breast cancer care. Ready to be part of the experience? Watch her message and register today to secure your place at the forefront of early breast cancer treatment! 🔗 Register now https://lnkd.in/d3Tv2SBN #BreastCancerCare #JoinUsInVienna #MedicalConference #SGBCC2025